Is NewAmsterdam Pharma financially healthy?
Yes
NewAmsterdam Pharma holds more cash than debt.
The numbers behind it
Net debt / EBITDANet cash
Cash vs. debt$490M vs. $202,000
Current ratio9.8×Short-term assets for each $1 of bills due within a year
How we decide
We measure debt in years of earnings (net debt / EBITDA): under 1 is very comfortable, 1 to 3 is manageable, above 3 is heavy. A company that earns less than 3 times its interest bill also counts as weak.
More questions about NewAmsterdam Pharma
Data as of Nov 13, 2026.